IOPtima device shows promise for glaucoma

09/21/2007 | Israel21c

Israel-based IOPtima Ltd. has developed OT134, a carbon dioxide laser device that allows eye surgeons with less training to more easily operate on patients with glaucoma. "Our system offers better efficacy and safety advantages, as well as the risk of far fewer complications over traditional drug and surgery therapies for glaucoma," CEO Joshua Degani said.

View Full Article in:

Israel21c

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ